MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/medsci14020311

Медицинская библиотека · Medical sciences (Basel, Switzerland) · 2026

Evaluating the Role of Chemotherapy in Addition to Radiotherapy for High-Risk Merkel Cell Carcinoma.

Brenner Ronen, Frumin Edri Hanna T, Meirovitz Amichay, El-Saied Sabri, Rouvinov Keren, Berezhnov Ilia, Ievko Anna, Turaieva Sofiia, Fenig Shlomit, Yasin Nashat Abu, Fenig Eyal, Hussany Samer, Shrem Noa Shani, Yakobson Alexander, Shalata Walid

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy with a high risk of recurrence. While adjuvant radiotherapy is standard following surgical resection in high-risk disease, the additional benefit of platinum-etoposide chemotherapy and the prognostic role of tumor anatomical location remain uncertain.

METHODS

We conducted a multicenter retrospective cohort study including patients with high-risk MCC (stage IIB-III) treated with surgery followed by adjuvant radiotherapy with or without platinum-etoposide chemotherapy. Tumor sites were classified according to sun-exposure status. Disease-free survival (DFS) and overall survival (OS) were estimated using Kaplan-Meier methods and compared using the log-rank test, with subgroup analyses by anatomical region and stage.

RESULTS

A total of 103 patients were included, of whom 77 (74.8%) received adjuvant chemoradiotherapy and 26 (25.2%) received radiotherapy alone. Patients with non-sun-exposed tumors demonstrated longer survival outcomes than those with sun-exposed tumors, with a median DFS of 57 months versus 42 months (p = 0.15), and a median OS of 179 months versus 109 months (p = 0.054), respectively. Among patients with sun-exposed tumors, chemoradiotherapy was associated with numerically improved DFS (42 vs. 34 months; p = 0.051) and OS (128 vs. 98 months; p = 0.08) compared with radiotherapy alone. In patients with non-sun-exposed tumors, chemoradiotherapy demonstrated a more pronounced improvement in OS (178 vs. 56 months; p = 0.054), while DFS also favored combined treatment (49 vs. 78 months; p = 0.078).

CONCLUSIONS

In this multicenter cohort, adjuvant chemotherapy did not demonstrate a uniform survival benefit overall but was associated with improved outcomes in head and neck MCC, suggesting a potential site-specific effect. Similar outcomes across stage III subgroups suggest that chemotherapy may mitigate stage-related prognostic differences. These findings support a selective approach to adjuvant chemotherapy and highlight the need for prospective studies incorporating modern immunotherapy strategies.

Для цитирования: Brenner Ronen, Frumin Edri Hanna T, Meirovitz Amichay, El-Saied Sabri, Rouvinov Keren, Berezhnov Ilia, Ievko Anna, Turaieva Sofiia, Fenig Shlomit, Yasin Nashat Abu, Fenig Eyal, Hussany Samer, Shrem Noa Shani, Yakobson Alexander, Shalata Walid. Evaluating the Role of Chemotherapy in Addition to Radiotherapy for High-Risk Merkel Cell Carcinoma.. Medical sciences (Basel, Switzerland). 2026. DOI: 10.3390/medsci14020311.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.